Introduction
Human B cell ontogeny can be divided into an antigen-independent stage that takes place in the bone marrow and an antigen-dependent stage which occurs in the peripheral lymphoid organs. The first stage is characterized by commitment of multipotent hematopoietic stem cells to 'common lymphoid stem cells' that then further expand and differentiate within the bone marrow. Differentiation of pro-B to pre-B cells is associated with the sequential transcription of lymphoid regulatory genes, and somatic gene rearrangements of immunoglobulin heavy chains. 1, 2 Rearrangement of the light chain allows immature B cells to express intact surface IgM, whereas mature B cells express both IgM and IgD. 1, 2 In addition, B cell differentiation is associated with the sequential expression of a variety of markers including CD38, CD19, CD20, CD22, CD23. 1 The mature B cell enters the circulation as an antigen naive cell. When naive B cells encounter Tdependent antigen in the periphery the second stage of differentiation occurs which results in the production of either longlived memory B cells or immunoglobulin producing plasma cells. 1, 2 The exact nature of signals required for this highly regulated and complex development is not yet known. This has impeded the development of in vitro models to study B lymphopoiesis. Whitlock immature B cells has been shown. 4 In vitro models of CD34 +
CD38
− cord blood cells have demonstrated differentiation to pro-B cells, 5 and more recently differentiation to IgM and IgG secreting B cells has been achieved. 6 These and other studies have demonstrated that successful B cell growth requires contact with hematopoietic stroma and low concentrations of serum but no hydrocortisone. Some, but not all, studies have shown that addition of cytokines such as FLT3L, SCF and IL7 improve B cell generation in either murine or human systems. 1, 5, [7] [8] [9] [10] [11] [12] Miller et al 13 have recently shown that pro-B cells can be generated from adult bone marrow CD34
− cells. Also, later stages of antigen-dependent B lymphopoiesis have been replicated using mature B cells from the peripheral blood or tonsil. These studies have identified IL4, IL5, IL6, and IL10, CD40 ligand, and antigen stimulation as some of the factors influencing terminal differentiation to memory or plasma cells. 2, 14, 15 However, systems that support generation of mature B cells from adult bone marrow pro-B cells have not been described. Such an in vitro model would be useful to investigate the essential early steps in B cell development and to study the biology of B lymphoid malignancies such as multiple myeloma and non-Hodgkin lymphoma.
We describe here a culture system that allows differentiation of adult human marrow derived CD34 + CD10 + CD19 − cells, containing common lymphoid progenitors 16 and early pro-B cells 17 to mature B cells. This is accomplished by culturing cells in contact with the murine fetal liver fibroblast feeder AFT024 and the sequential addition of cytokines known to be important in antigen-independent and -dependent B cell development, CD40 ligand and a polyclonal B cell mitogen. Our model thus replicates early human B lymphopoiesis in vitro in a single system, and should be an important tool for the further investigation of B cell development and B cell malignancies.
Materials and methods

Cell source and selection
Bone marrow was obtained from healthy adult volunteers (18- 
Cell culture Stromal Feeders:
AFT024 and 2018 murine fetal liver fibroblast feeders immortalized by a retrovirus containing a temperature sensitive SV40 T antigen (kind gifts from IR Lemischka, Princeton University, NJ, USA) were maintained in DMEM (Gibco) supplemented with 20% fetal calf serum (FCS) (Hyclone Laboratories, Logan, UT, USA), 50 mM 2-mercaptoethanol (Bio-Rad, Hercules, CA, USA) at 33°C. AFT024 and 2018 cells were subcultured at 33°C in 24-well plates (Costar, Cambridge, MA, USA) precoated with 0.1% gelatin (Specialty Media, Lavalette, NJ, USA). When confluent, AFT024 and 2018 feeders were irradiated at 2000 rad and maintained at 37°C. S17 cells (a kind gift from K Dorshkind, University of California, CA, USA) were grown in RPMI-1640 (Gibco) and 10% FCS at 37°C, subcultured in 24-well plates, and irradiated at 2000 rad when confluent. M2-10B4 cells (a kind gift from C Eaves, Terry Fox Laboratories, Vancouver, Canada) were grown in RPMI-1640 and 10% FCS, subcultured in 24-well plates, and were irradiated at 6000 rad when confluent.
Media:
B cell culture medium consisted of X-VIVO10 media (Biowhittaker, Walkersville, MD, USA), supplemented with 5% FCS (Hyclone), 25 mM 2-mercaptoethanol (Bio-Rad), 2 mmol/l L-glutamine (Gibco), 1000 U/ml penicillin and 100 U/ml streptomycin (Gibco). We also tested RPMI-1640 and 5% heat inactivated human serum (NABI; NormlCera-Plus, Miami, FL, USA).
Cytokines:
We used FLT3 (a gift from Immunex, Seattle, WA, USA), SCF and IL2 (gifts from Amgen, Thousand Oaks, CA, USA), and IL3, IL4, IL5, IL6, IL7, IL10 and IGF1 (R&D Systems, Minneapolis, MN, USA).
Other ingredients:
Other ingredients included soluble CD40 antibody (Biosource International, Camarillo, CA, USA), and Staph. aureus Cowan (SAC) particles (Calbiochem, La Jolla, CA, USA).
Bulk cultures:
FACS selected cells were suspended in B cell culture medium and plated in contact with stromal feeders at 5000 cells/well in 24-well plates. CD34 
CD19
+ cells were only cultured for 2 weeks. 10 ng/ml FLT3L, 10 ng/ml SCF, 20 ng/ml IL7, 20 ng/ml IGF1, 100 units/ml IL2, and 5 ng/ml IL3 were added on days 0, 7, 14 and 21. IL4, IL5, IL6 and IL10 (all at 10 ng/ml) and 1 g/ml soluble CD40 antibody were added on days 14, 21 and 28, and 10 l/ml of a 0.005% solution of SAC particles was added on days 21 and 28 ( Figure   Leukemia 
1). CD34
− CD19 + cells were cultured with FLT3L, SCF, IL7, IGF1, IL2, IL3, IL4, IL5, IL6, IL10, CD40 antibody and SAC particles on days 0 and 7 all at the same concentrations as described above.
Calculation of cell expansion
Cells were harvested, resuspended in 1 ml of PBS (Sigma), and 40 ml were stained with trypan blue solution 0.04% (Sigma). Viable hematopoietic cells, distinguished from stromal cells by their size difference and exclusion of dye, were counted manually using a hematocytometer. Total cell expansion was calculated by dividing the number of viable hematopoietic cells by the number of input cells. The percentage of CD19 
Flow cytometry
Day 0 CD34 + cells and cultured cells harvested at 2, 3 and 4 weeks using trypsin EDTA (Sigma) were labeled with PE, FITC or APC-conjugated monoclonal antibodies, fixed with 2% paraformaldehyde (Sigma), and analyzed on a FACS-caliber. The following antibodies were used: CD15 FITC, CD19 PE, CD20 PE, CD22 PE, CD23 FITC, CD34 PE, CD38 PE, CD38 APC, CD56 PE, all from BDIS. CD21 FITC, anti-human IgM heavy chain FITC, anti-human IgG heavy chain FITC and antikappa and lambda FITC were obtained from Pharmingen. Anti-human IgD heavy chain FITC was obtained from Sigma. CD138 FITC was purchased from Serotec (Raleigh, NC, USA). Samples were analyzed using appropriate isotype controls (BDIS). Results were acquired and analyzed using BDIS Cellquest software. 
Immunoglobulin analysis
To determine if B cells secreted IgM or IgG, media conditioned by differentiating B cells were collected at 4 and 5 weeks of culture and stored at −20°C until testing. An ELISA plate (Nunc, Naperville, IL, USA) was coated with isotypespecific anti-human immunoglobulin (Ig) (Sigma) in NaHCO 3 (0.1 mol/l, pH 8.3) with NaNH 3 (0.2 g/l) at 4°C. The plate was washed with washing buffer (PBS, pH 7.4, with 0.05% Tween20) and incubated with samples in dilution buffer (0.05 mol/l Tris, pH 8.1, MgCl 2 1 mmol/l, NaCl 0.15 mol/l, 0.05% Tween20, 0.2 g/l NaNH 3 and 10 g/l BSA) overnight at 4°C. The plate was then washed thoroughly and incubated with alkaline phosphatase conjugated goat anti-human IgG or IgM antibody (Sigma) (1:1000 to 1:3000 dilution) for 2 h at room temperature. The color was developed by adding a solution of 104 phosphatase substrate (Sigma) at room temperature. Ig amount was quantified by measuring the Ig level in six serial dilutions of the sample and comparing the data with a standard curve generated using purified human Ig (Sigma). 18 
Epstein-Barr virus detection
To determine if B cell growth was due to infection with Epstein-Barr virus (EBV), cultures of CD34
+ cells were harvested, at 3 and 2 weeks respectively, and cells were stored at −80°C until analysis. DNA was extracted using the PureGene System (Gentra Systems, Minneapolis, MN, USA). 0.15 ng DNA was amplified by adding 1 U AmpliTaq DNA polymerase (Perkin Elmer, Applied Biosystems Division, Foster City, CA, USA), 0.15 mM EBV sense primer (5Ј-GCAGTAACAGGTAATCTCTGG-3Ј), 0.15 mM EBV antisense primer (5Ј-CCAGAAATAGCTGCAGGACC-3Ј), which amplify a 401 bp portion of the BamHI W EBV fragment, 0.25 mM MgCl 2 , and 0.025 mM of each dNTP (Promega Corporation, Madison, WI, USA). As an internal control, 0.3 mM p53 gene sense primer (5Ј-TATCCTGAGTAGTGGTAATC-3Ј) and 0.3 mM p53 antisense primer (5Ј-AAGTGAAT CTGAGGCATAAC-3Ј), which amplify exon 8 of the p53 gene, were included in each reaction. Each PCR run included an FJO cell line sample (American Type Culture Collection, Rockville, MD, USA), a well characterized EBV-positive B lymphoblast cell line, as a positive control. DNA was amplified using the following thermal cycler parameters: 94°C for 3 min, 30 cycles of 39°C for 1 min, 59°C for 30 s, and 72°C for 30 s. PCR products were electrophoresed on a Novex precast 6% polyacrylamide gel (Novex Corporation, San Diego, CA, USA) at 100 V for 1 h. Products were analyzed after staining the gels with ethidium bromide. 19 
Statistics
Results of experimental points from different experiments were reported as the mean ± standard error of the mean (s.e.m.). Significance levels were determined by paired Student's t-test analysis.
Results
Cell populations
For most experiments we used CD34
+ cells selected on a FACS Star Plus flow cytometer. These cells had typical flow cytometry characteristics of lymphoid cells with low forward and side scatter, and a post sort purity of 98 ± 0.5% and were 58 ± 5.5% CD19 
CD19
− cells was 94 ± 1.5%, and 83 ± 6.6% for the CD34
+ cells.
Development of the B cell culture system
In the development of the culture system we evaluated which components were imperative for the maximal generation of CD34 − CD19 + pre-B cells from CD34 + CD38 + CD10 + cells and their differentiation into mature B cells. As 2018, S17 and M2-10B4 feeders are known to support B lymphopoiesis, they were chosen for comparison to AFT024. We found that AFT024, a SV40 transformed murine fetal liver fibroblast feeder, was superior to the other feeders in support of CD19 + B cell proliferation from CD34
+ progenitors. AFT024 resulted in a two-fold and three-fold superior expansion at day 14 than 2018 and S17 respectively (n = 4) and M2-10B4 did not support proliferation of these cells (n = 2). We also found that CD19 + B cell growth occurred maximally in X-VIVO10 with 5% fetal calf serum supplementation whereas other media, such as RPMI-1640 with 5% FCS, X-VIVO10 with 5% human serum or X-VIVO10 without serum supplement were less supportive (n = 3).
To assess the factors needed to maximize expansion of CD19 + B cells at later stages of differentiation, we used CD34 −
CD19
+ B cells cultured on AFT024 in B cell media with early and late acting cytokines all added on day 0. We compared cytokines alone, cytokines and CD40 antibody, and cytokines, CD40 antibody and SAC particles. We observed that addition of CD40 antibody, and addition of CD40 antibody + SAC, stimulated a two-fold and four-fold greater expansion of CD34 −
+ cells respectively, above that seen with cytokines alone at day 10 in culture (n = 3). For this reason we adopted CD40 antibody plus SAC particles in addition to the early and late acting cytokines as our standard culture approach for CD34 
Generation of immunoglobulin secreting immature and mature B cells
CD10
+ cells in contact with AFT024 feeders in X-VIVO10, 5% FCS, FLT3L, SCF, IL7, IGF1, and including IL2 and IL3, resulted in a 31.9 ± 4.6-fold cell expansion at week 2 of which 31% were CD19 + B cells. The CD19 + cells harvested at this time were no longer CD34 + , had acquired the B cell markers CD20 and CD22, and had little or no surface IgM or surface kappa/lambda light chains, indicating that the majority were pre-B cells. The CD19 − cells present after 2 weeks of culture included 9.8 ± 3.2% CD34 − CD56 + NK cells and 5.6 ± 1.0% CD15 + myeloid cells. The nature of remaining CD19 − cells was not identified, but they were not CD3 + T cells, which were not detected at any stage. After 2 weeks in culture (day 14) we added IL4, IL5, IL6, IL10 and CD40 antibody, and after 3 weeks (day 21) we added SAC particles. The absolute number of CD19 + cells generated per CD34 + CD38 + CD10 + cells was maximal at day 14 and declined at 3-4 weeks in culture. After 3 weeks 17.3 ± 2.5% of CD19 + cells expressed surface IgM and 19.5 ± 2.6% expressed surface light chains demonstrating the generation of immature B cells. By 4 weeks, 16.5 ± 4.5% of CD19 + cells expressed surface IgD indicating generation of mature B cells (Figures 3 and 4) . This was associated with the acquisition of CD23. In five of 11 experiments we detected 109.9 ± 27.8 ng/ml soluble IgM in the culture media at 4-5 weeks of culture. In the remaining experiments IgM levels were below levels of detection routinely used for this assay. No IgG + B cells or CD38 ++ CD138 + plasma cells were identified, and no IgG was detected in the culture media. 
Exclusion of Epstein-Barr virus (EBV) infection
To exclude the possibility that B cell growth was due to EBV infection, cells were harvested from CD34
+ cultures (n = 6) and CD34
−
CD19
+ cultures (n = 4) and assayed for EBV by PCR. No EBV genome sequences were amplified, demonstrating that EBV was not responsible for the B cell proliferation. This is consistent with the finding that B cell proliferation was polyclonal (data not shown).
Role of IL2 and IL3 in B cell culture
Experiments were then performed to identify the importance of IL2 and IL3 in the maximal production of CD19 + cells from CD34
+ cells ( Figure 5 ). We showed that IL2 and IL3 were not necessary for the generation of CD19 + B cells. In fact, the four cytokine combination of FLT3L, SCF, IL7 and IGF1 at day 0, without IL2 and IL3, promoted a significantly greater growth of CD19 + B cells from CD34
Total cell expansion was 28.5 ± 7.9 at day 14, and 8.8 ± 0.9 at day 25. The removal of IL2 and IL3 promoted growth of the greatest proportion of CD19 + cells from the pro-B cells. Eighty and 76% of these cells were CD34 − CD19 + B cells at days 14 and 25, respectively (day 25 in Figure 5 , P = 0.04). Inclusion of IL2 with FLT3L, SCF, IL7, and IGF1 promoted CD56 + NK cell differentiation, whereas addition of IL3 with these four cytokines stimulated the growth of CD15 + myeloid cells.
Role of sequential addition of cytokines in B cell culture
We also tested our initial hypothesis that sequential addition of early and late acting cytokines is required for optimal CD19 + B cell development from CD34 + CD38 + CD10 + cells ( Figure 6 ). We found that cultures supplemented with the early acting cytokines (FLT3L, SCF, IL7, IGF1, IL2, IL3 ) only for 3-4 weeks (without late acting cytokines), or these early and the
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Figure 5
Effect of IL2 and IL3 in the early cytokine combination on the generation of CD19 late acting cytokines IL4, IL5, IL6, IL10, all given on day 0 for 3-4 weeks, generated significantly less CD19 + B cells (P Ͻ 0.02, Figure 6 ), and significantly less light chain positive immature and mature B cells (data not shown). This confirmed that the initial addition of early acting cytokines, and then subsequent addition of late acting cytokines with CD40 antibody, allowed for optimal proliferation of CD19 + B cells and the differentiation of immature and mature B cells. 
Generation of immature and mature B cells from
CD19
+ cells cultured in B cell conditions (as in Figure 1 ) generated CD19 
+ population with a small fraction of CD19
− cells (11.5 ± 2.3% NK cells vs 0.5 ± 0.5% at day 28). 
+ populations at day 21 (paired Student's t-test).
Discussion
In this work we describe for the first time an in vitro model that supports differentiation of adult bone marrow-derived pro-B cells to mature immunoglobulin-secreting B cells in a single culture system. This is achieved by culturing pro-B cells for 4 weeks in contact with the murine fetal liver feeder AFT024, with the sequential addition of early and late acting cytokines, a ligand to CD40, and a polyclonal B cell mitogen. These studies confirm and extend results from Fluckiger et al 6 who recently published that differentiation of uncommitted CD34 + CD38 − umbilical cord blood cells to mature IgG-positive B cells can be achieved in vitro. In contrast to the Fluckiger system, we used adult bone marrow as the source of hematopoietic cells. In addition, we developed a one-stage culture system, whereas Fluckiger et al transfer red cells from the murine stromal feeder S17 to a CD40 ligand gene transfected feeder.
We showed that development of IgM-positive immature B cells can be achieved using either CD34 + CD10 + CD19 + cells (containing pro-B cells 17 ) or CD34
cells, thought to contain less committed cells, including the common lymphoid progenitor cell. 16 To definitively prove that our system allows differentiation to B cells from a common lymphoid progenitor (ie capable of generating NK cells as well as B cells) will require single cell sorting. However, as alluded to earlier, Miller et al demonstrated that uncommitted CD34
− cells can generate pro-B cells, as well as myeloid and NK cells. Therefore, we speculate that our assay may be capable of inducing common lymphoid progenitors to differentiate to surface immunoglobulin positive B cells.
An important component of our system is the AFT024 stromal feeder. Whitlock and Witte 3 first demonstrated the importance of stromal support in murine B lymphopoiesis in 1982. It has since been shown that human B cell development is dependent on direct contact with stroma as well as soluble factors released by stromal cells. 20, 21 ␤1 integrin-mediated adhesion to stromal fibronectin and VCAM is one of the mechanisms underlying the supportive and anti-apoptotic effects of stroma on B cells. [20] [21] [22] More recently, other stromal molecules such as the matrix glycoprotein SC1/ECM, have been shown to facilitate the growth of pre-B lymphocytes. 23 We used the murine fetal liver feeder AFT024 described by Moore et al 24 for our B cell culture. We found that the AFT024 feeder was superior to other stromal feeders also known to support B lymphopoiesis such as 2018, 25 S17 26 and M2-10B4. 27 Miller et al 13 have shown that the same AFT024 feeder supports generation of pre-B cells from adult bone marrow and cord blood CD34 + Lin − CD38 − stem cells. The mechanisms underlying the superior support of AFT024 for hematopoietic stem cells, and possibly B lymphopoiesis, is currently being investigated. 28 The combination of FLT3L, IL7, SCF and IGF1 stimulated an optimal expansion of CD19 + B cells from CD34
Multiple investigators have recognized the importance of FLT3L, SCF and IL7 in B cell development. 1, 5, [7] [8] [9] [10] [11] [12] [13] 15, 20, 29 We also included IGF1 in our cytokine combination as it has been shown to support early murine B lymphopoiesis. 1, 30 We tested the role of IL2 and IL3 in early B lymphopoiesis. IL3 has been shown to be stimulatory to early human B lymphopoiesis 31 but the work of Ogawa's group has suggested that IL3 is inhibitory to B cell development in mice. 32 Interestingly, we showed that IL2 and IL3 are not necessary for pro-B cell proliferation and differentiation. Significantly more CD19
+ B cells were generated from CD34
CD10
+ cells with FLT3L + Leukemia SCF + IL7 + IGF1 than cultures containing this combination with IL2 and IL3. This may be at least partly because IL2 and IL3 promoted NK and myeloid proliferation within the culture, respectively. To induce further B cell differentiation we included IL4, IL5, IL6 and IL10. These have been described to promote B cell proliferation during the antigen-dependent stage, and promote inhibition of apoptosis, immunoglobulin isotype switch and production, and terminal differentiation. 14, 15, [33] [34] [35] We also included soluble CD40 antibody to mimic CD40L expressed on activated T helper cells. CD40L is required for B cell proliferation and prevention of apoptosis during the antigendependent stage of B cell development.
36 CD40L is also required for immunoglobulin isotype switching, immunoglobulin production, and formation of memory B cells. 36 SAC particles, known to stimulate the BCR, were included to act as a polyclonal mitogen. 14 We demonstrate that soluble CD40 antibody may be used to induce B cell maturation, and may be able to replace the cell surface CD40 ligand expression as used in the assay described by Fluckiger et al. 6 In contrast to the Fluckiger cord blood system, 6 we were not able to induce isotype switch or terminal differentiation. In other studies done in our laboratory, we have found that the same AFT024-based culture system supplemented with late acting cytokines can induce differentiation of marrowderived CD34
− CD19 + IgD + B cells and CD34 − CD19 + IgG + B cells to plasma cells (unpublished data). However, when using pro-B cells as the input cells, we could not stimulate differentiation beyond the immature and mature B cell stage. This discrepancy may indicate that the IgD + B cells derived in culture from CD34
+ pro-B cells differ from mature B cells obtained from fresh bone marrow. Further, the differentiation block seen in our studies, which was not seen in the Fluckiger paper, may indicate that the CD40 signal given by soluble antibody is less potent than that provided by cell surface CD40L. Alternatively, or in addition, other cells generated in the system may be inhibitory to the further differentiation of the B cells in our cultures. Other possibilities include that incorrect timing of BCR stimulation or excessive stimulation by SAC particles may have induced apoptosis. Additional T helper cell or dendritic cell-mediated signals may assist in isotype switch and terminal differentiation.
In conclusion, we show that our culture method replicates early B lymphopoiesis from early adult bone marrow pro-B cells to mature B cells in a single system. This system will be extremely useful for the further study of both normal and malignant B lymphopoiesis.
